Company Liquidation LTD

Company profile

Cis Oncology Limited

UK company 02431816, incorporated on 12 October 1989.

CIS Oncology | Experts in Automated Chemotherapy Prescribing

Our ChemoCare system is used by hundreds of NHS trusts across the UK and makes prescribing and patient management quicker, easier and more reliable, using the latest technology for access anywhere, any time.

Company number
02431816
Incorporated
12 Oct 1989
Companies House status
Liquidation

Company identity

Founded / incorporated
12 October 1989

Company number 02431816

Verify at Companies House
Legal name
CIS ONCOLOGY LIMITED
Company type
Private Limited Company
Region
South East England
Registered address
FIRST FLOOR, PARK CENTRAL
PARK END STREET
OXFORD
ENGLAND
OX1 1JD
Insolvency history
No

Corporate ownership

Updated 07 Jul 2026 09:49

8 levels 1 ultimate controller
1
Company Liquidation LTD
Cis Oncology Limited
CRN 02431816
2
Direct controller Active LTD
Cis Healthcare Limited
CRN 06001875
3
Intermediate controller Active LTD
4
Intermediate controller Active LTD
5
Intermediate controller Active LTD
6
Intermediate controller Active LTD
7
Intermediate controller Active LTD
8
Intermediate controller Active LTD
9
Ultimate controller
00140080
CRN 00140080

Company events

Reference milestones and recent Companies House filing stream events.

5 events
31 Oct
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

31 Mar
2026

Accounts due

Accounts Due

Next accounts due date

17 Oct
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Mar
2024

Accounts filed

Accounts

Last accounts made up date

12 Oct
1989

Incorporated

Inception

Company registered at Companies House

Public funding

1 award
First funded
2011
Funded years
2011
Age at first award
22 years

Projects

2011 Collaborative R&D

Development of a fully integrated service for sequencing-based tumour profiling including data interpretation and commercialisation of assay panel kit products

1 Dec 2011 to 31 Dec 2014

Awarded
£147,319
Total cost £368,482

The aim of this project is to develop a tumour profiling assay based on targeted multiplexed enrichment and next generation sequencing (NGS) of clinically informative genes and variants. Oxford Gene Technology (OGT) will work closely with its partners in Birmingham and Southampton, and the CR-UK Technology hubs to build the assay into an innovative, integ...

Product types

Collaborative R&D